77 results about "Alzheimer dementia" patented technology

Methods and compositions for treating or preventing, the occurrence of senile dementia of the Alzheimer's type, or other conditions arising from reduced neuronal metabolism and leading to lessened cognitive function are described. In a preferred embodiment the administration of triglycerides or fatty acids with chain lengths between 5 and 12, to said patient at a level to produce an improvement in cognitive ability.

The invention discloses a traditional Chinese medicine for preventing and treating Alzheimer disease and a preparation method thereof. The traditional Chinese medicine is prepared from the following raw materials in parts by weight: 12-16 parts of prepared fleece flower root, 8-12 parts of ginseng, 9-13 parts of rhizoma acori graminei, 5-9 parts of coptis and 6-10 parts of chuanxiong rhizome. The traditional Chinese medicine can be prepared into granules, capsules, soft capsules, dissolved medicines, dripping pills and soft extracts, has the advantages of simple manufacturing process and low cost, is completely prepared from natural plants, does not contain hormones, has no addition of pigments and other chemical synthetics, and does not have toxic side effects on human bodies after being continuously used. The traditional Chinese medicine contains various effective components such as flavones, saponins, phenolic acids, alkaloids, polysaccharides and the like capable of being easily absorbed by human bodies, can be effectively used for nourishing the kidney and invigorating the brain, replenishing qi and dissolving turbidity and promoting blood circulation and eliminating toxicity, and is suitable for treating deficiency of the kidney, mild cognitive impairment caused by obstruction of the orifices by blood stasis, Alzheimer disease and the like.

The invention relates to a drug, in particular to a drug composition for improving dysmnesia alzheimer disease and a preparation method thereof. The drug composition of the invention is made of the following raw medicines according to the parts by weight of 90 grams of gymnadenia conopsea, 90 grams of radix polygoni multiflori preparata, 90 grams of acanthopanax, 90 grams of sealwort, 90 grams of milk veteh, 60 grams of angelica, 60 grams of medlar, 60 grams of shizandra berry, 60 grams of dogwood, 60 grams of polygala, 60 grams of grassleaf sweelflag rhizome, and 60 grams of red paeonia. The drug composition of the invention is made of fully natural Tibetan pharmaceuticals with high quality and without pollution and traditional Chinese medicines which are mixed reasonably and does not have any side effect. The drug composition for improving dysmnesia alzheimer disease is widely applied to school students younger than eighteen years old and the middle and old-aged brainworkers elder than 45 years old to take as well as the symptoms of feeblemindedness, dysmnesia and alzheimer disease, etc.

An alkyl ether derivative represented by the formula:wherein R1, R2, R3, R4, m and n are as defined in the specification, or salts thereof exhibits synergistically improved anti-hypoxic activity when combined with a compound having an acetylcholine esterase inhibitory activity. Therefore, the combination according to the present invention is useful as a method for improving cerebral function. Further, a pharmaceutical composition containing the compound relating to the combination according to the present invention is useful for treatment and prevention of dysfunction of cerebral acetylcholine neurons in the sequelae of cerebrovascular dementia, senile dementia, Alzheimer's disease and ischemic cerebral lesion and in the cerebral apoplexy or the memory impairment caused by selective neuronal death.

This invention is directed to compounds of the following formula: wherein when a is 0, b is 1 or 2; when a is 1, b is 1, m is from 0-3, X is O or S, Y is halogeno, R1 is hydrogen C1-4 alkyl, R2 is hydrogen, C1-4 alkyl, or optionally substituted propargyl and R3 and R4 are each independently hydrogen, C1-6 alkyl, C6-12 aryl, C6-12 aralkyl each optionally substituted.This invention is also directed to the use of these compounds for treating depression, Attention Deficit Disorder (ADD), Attention Deficit and Hyperactivity Disorder (ADHD), Tourette's Syndrome, Alzheimer's Disease and other dementia's such as senile dementia, dementia of the Parkinson's type, vascular dementia and Lewy body dementia.This invention is further directed to a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

Furanone derivatives and the pharmaceutically acceptable salts thereof have cytoprotective activity and protective activity for neuroinflammation, and neurodegenerative disorders; they are useful in the treatment of stroke, cerebral ischemia, myocardial infarction, myocardial ischemia, chronic heart failure, inflammation and other oxidative stress-related conditions, as well as Alzheimer's disease and senile dementia; they are also useful in the manufacture of pharmaceutical formulations for the treatment of such conditions.

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-amido-aryl compounds of the following formula (for convenience, collectively referred to herein as “AAA compounds”), which, inter alia, are (selective) retinoic acid receptor α (RARα) agonists. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) activate RARα, and in the treatment of diseases and conditions that are mediated by RARα, that are ameliorated by the activation of RARα, etc., including cognitive disorders, memory impairment, memory deficit, senile dementia, Alzheimer's disease, early stage Alzheimer's disease, intermediate stage Alzheimer's disease, late stage Alzheimer's disease, cognitive impairment, and mild cognitive impairment.

The present invention provides an agent for improving mental disorders due to cerebral dysfunction and an agent for inhibiting vascular hyperpermeability each containing a hepatocyte growth factor. The agent for improving mental disorders according to the present invention is useful in improving mental disorders, particularly decline in learning and memory function, due to cerebral dysfunction occurred in blood circulation disorders in the brain (for example, cerebral infarction, cerebral hemorrhage, lacunar stroke, Biswanger's disease, cerebral thrombosis, subarachnoid hemorrhage, cerebrovascular moyamoya disease, carotid cerebral arterial fibrous muscular plasia, cerebral arterial sclerosis, internal carotid artery occlusion, hypertensive encephalopathy, cerebral edema, etc.) and neurodegenerative disorders (for example, multiple sclerosis, Parkinson's disease, Parkinson'syndrome, Huntington's chorea, cerebrovascular dementia and Alzheimer dementia), epilepsy, head injury, etc. The agent for inhibiting vascular hyperpermeability according to the present invention is efficacious to blood hyperpermeability in the brain due to blood circulation disorders in the brain (for example, cerebral infarction, cerebral hemorrhage, lacunar stroke, Biswanger's disease, cerebral thrombosis, subarachnoid hemorrhage, cerebrovascular moyamoya disease, carotid cerebral arterial fibrous muscular plasia, cerebral arterial sclerosis, internal carotid artery occlusion, hypertensive encephalopathy, cerebral edema, etc.), blood leakage, edema, subcutaneous hemorrhage and bleeding tendency due to vascular hyperpermeability in various tissues (including internal organs).

The invention relates to the technical field of antibody drugs, in particular to a humanized anti-A[beta] monoclonal antibody and an application thereof. The humanized anti-A[beta] monoclonal antibodyprovided by the invention can inhibit A[beta] monomer polymerization and protect nerve cells from being infected with A[beta] toxicity, has a certain effect of improving cognitive learning and memoryability of Alzheimer dementia model mice, and can be used for treatment and diagnosis of diseases and symptoms related to amyloidosis, such as the Alzheimer disease.

The invention belongs to the technical field of immunity, in particular relates to recombinant antigen polypeptide for preventing and treating senile dementia and a fusion gene encoding the recombinant antigen polypeptide. The recombinant antigen polypeptide contains at least one immunopotetiation sequence and at least one human beta-amyloid peptide sequence, wherein, the human beta-amyloid peptide sequence is provided with an amino acid sequence as shown in SEQ ID NO:1 or SEQ ID NO:2, the immunopotetiation sequence is selected from SEQ ID NO:3, SEQ ID NO:4, a recombinant form of the SEQ ID NO:3 and the SEQ ID NO:4 or an amino acid sequence which has at least 90% homology with the two. The recombinant antigen polypeptide removes carboxyl-terminal toxic fragment of full-length human Abeta, improves safety of the antigen peptide Abeta, and recombines the immunopotetiation sequence, and enhances the immunogenicity of the antigen peptide Abeta.

The invention discloses a pill composition used for preventing and treating Alzheimer disease and a preparation method thereof, in particular a pill composition used for preventing and treating the Alzheimer disease, which is prepared from an active ingredient (-)-epigallocatechin gallate (EGCG) and pharmaceutically acceptable accessories, and a preparation method for the pill composition. The invention has the outstanding characteristic of providing the pill composition which is safe, effective, quality-controllable and convenient to use for patients suffering from the Alzheimer disease.